IRMD vs. SLNO, NVST, LIVN, WRBY, INSP, EYE, LQDA, LMAT, AORT, and PRCT
Should you be buying iRadimed stock or one of its competitors? The main competitors of iRadimed include Soleno Therapeutics (SLNO), Envista (NVST), LivaNova (LIVN), Warby Parker (WRBY), Inspire Medical Systems (INSP), National Vision (EYE), Liquidia Technologies (LQDA), LeMaitre Vascular (LMAT), Artivion (AORT), and PROCEPT BioRobotics (PRCT). These companies are all part of the "medical equipment" industry.
iRadimed vs. Its Competitors
Soleno Therapeutics (NASDAQ:SLNO) and iRadimed (NASDAQ:IRMD) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.
iRadimed has a net margin of 26.61% compared to Soleno Therapeutics' net margin of 0.00%. iRadimed's return on equity of 23.30% beat Soleno Therapeutics' return on equity.
Soleno Therapeutics presently has a consensus target price of $115.92, indicating a potential upside of 73.27%. iRadimed has a consensus target price of $72.00, indicating a potential downside of 7.19%. Given Soleno Therapeutics' higher probable upside, research analysts plainly believe Soleno Therapeutics is more favorable than iRadimed.
In the previous week, Soleno Therapeutics had 10 more articles in the media than iRadimed. MarketBeat recorded 13 mentions for Soleno Therapeutics and 3 mentions for iRadimed. iRadimed's average media sentiment score of 0.95 beat Soleno Therapeutics' score of 0.68 indicating that iRadimed is being referred to more favorably in the news media.
97.4% of Soleno Therapeutics shares are held by institutional investors. Comparatively, 92.3% of iRadimed shares are held by institutional investors. 6.4% of Soleno Therapeutics shares are held by company insiders. Comparatively, 36.8% of iRadimed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
iRadimed has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.
Soleno Therapeutics has a beta of -2.75, indicating that its stock price is 375% less volatile than the S&P 500. Comparatively, iRadimed has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500.
Summary
iRadimed beats Soleno Therapeutics on 11 of the 16 factors compared between the two stocks.
Get iRadimed News Delivered to You Automatically
Sign up to receive the latest news and ratings for IRMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
iRadimed Competitors List
Related Companies and Tools
This page (NASDAQ:IRMD) was last updated on 10/22/2025 by MarketBeat.com Staff